CIRM Funded Clinical Trials

GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE


Disease Area:
Investigator:
Institution:
CIRM Grant:
DR1-06893 (Closed)
Award Value:
$8,278,722.00
Trial Sponsor:
Trial Stage:
Phase 1/2
Trial Status:
Completed
Targeted Enrollment:
13
ClinicalTrials.gov ID:

Details:

Calimmune is genetically modifying patients’ own blood-forming stem cells (also known as bone marrow stem cells) so they can produce immune cells—the ones normally destroyed by the HIV virus—that cannot be infected by the virus. The goal of this treatment is to enable the patients to clear their systems of the virus, effectively curing the disease.

Design:

Single arm, non-randomized study.

Goal:

Safety. Efficacy - slow disease progression, mitigate need for ART.

Contact Trial Sponsor

CIRM Clinical Trial Resources


Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox


Video on Stem Cell Trials


Other Resources

ISSCR Patient Website

ClinicalTrials.gov